https://scholars.lib.ntu.edu.tw/handle/123456789/553855
標題: | CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells | 作者: | Chen K.-F. Liu C.-Y. Lin Y.-C. Yu H.-C. TSUNG-HAO LIU Hou D.-R. PEI-JER CHEN ANN-LII CHENG |
公開日期: | 2010 | 卷: | 29 | 期: | 47 | 起(迄)頁: | 6257-6266 | 來源出版物: | Oncogene | 摘要: | Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediates the apoptotic effect of bortezomib in HCC. Silencing PP2A by small interference RNA (siRNA) abolishes bortezomib-induced down-regulation of phospho-Akt and apoptosis. Bortezomib increases PP2A activity in sensitive HCC cells, including Sk-Hep1, Hep3B and Huh-7, but not in resistant PLC5 cells. Bortezomib down-regulates CIP2A in a dose- and time-dependent manner in all sensitive HCC cells, whereas no alterations in CIP2A were found in resistant PLC5 cells. Knockdown of CIP2A by siRNA restored bortezomibs effects on apoptosis and PP2A activity in PLC5 cells. Moreover, over-expression of CIP2A up-regulated phospho-Akt and protected Sk-Hep1 cells from bortezomib-induced apoptosis. It is significant that, ectopic expression of CIP2A decreased Akt-related PP2A activity, whereas silencing CIP2A increased this activity, indicating that CIP2A negatively regulates Akt-related PP2A activity in HCC cells, furthermore, our in vivo data showed that bortezomib down-regulates CIP2A and up-regulates PP2A activity in Huh-7 tumors, but not in PLC5 tumors. In conclusion, inhibition of CIP2A determines the effects of bortezomib on apoptosis and PP2A-dependent Akt inactivation in HCC. ? 2010 Macmillan Publishers Limited All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649511007&doi=10.1038%2fonc.2010.357&partnerID=40&md5=41f4f5d55140554939e2df45ad24bacd https://scholars.lib.ntu.edu.tw/handle/123456789/553855 |
ISSN: | 0950-9232 | DOI: | 10.1038/onc.2010.357 | SDG/關鍵字: | bortezomib; phosphoprotein phosphatase 2A; small interfering RNA; animal cell; animal experiment; animal model; apoptosis; article; cancer cell culture; dose response; down regulation; drug effect; enzyme inhibition; gene expression; gene silencing; in vivo study; liver cell carcinoma; male; mouse; nonhuman; priority journal; timed drug release; upregulation; Animals; Apoptosis; Autoantigens; Boronic Acids; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Knockdown Techniques; Humans; Male; Membrane Proteins; Mice; Mice, Nude; Phosphoproteins; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Transcription, Genetic; Tumor Markers, Biological; Up-Regulation; Xenograft Model Antitumor Assays |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。